Pathophysiologic Insights from Biomarker Studies in Neurological Disorders
Neuroimmunological and neurodegenerative disorders are major healthcare issues associated with high individual and socioeconomic burden. For many neurological disorders an early diagnosis is key for efficient management and therapy. However, neural tissues from brain, spinal cord or peripheral nerve...
Enregistré dans:
| Format: | Online |
|---|---|
| Langue: | anglais |
| Publié: |
Frontiers Media SA
2021
|
| Sujets: | |
| Accès en ligne: | ONIX_20211118_9782889636433_917 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1869524722558959616 |
|---|---|
| collection | Directory of Open Access Books |
| description | Neuroimmunological and neurodegenerative disorders are major healthcare issues associated with high individual and socioeconomic burden. For many neurological disorders an early diagnosis is key for efficient management and therapy. However, neural tissues from brain, spinal cord or peripheral nerves are difficult to obtain, and their extraction is often associated with functional deficits. Therefore, in most cases a combination of biomarkers such as radiologic or biochemical findings are used to define a diagnosis in the clinical practice. The development of pathologically-sensitive and easy-to-measure disease biomarkers is a key factor for investigating new medications in phase 2 trials aiming to quickly screen their efficacy, and in phase 3 trials where they are coupled to clinical measures. Moreover, biomarkers are used to predict treatment efficacy and adverse event risk, paving the way for personalized medicine with individual risk assessment and prevention strategies. In the last few decades the enormous technological progress, especially omics technologies, expanded the definition of biomarkers from biochemical and clinical by genetic, proteomic, metabolic or microbial markers. Interestingly, some of the biomarker studies additionally provided important insights into the pathophysiology of neurological disorders. In multiple sclerosis TNF-blocking drugs can promote onset or exacerbation of MS and GWAS (genome-wide association studies) data informed about the underlying mechanisms instructing clinical practice. In Parkinson’s disease (PD), evaluation of Lewy pathology provided new pathophysiological insights attributing PD pathology progression to a prion-like process starting in the gastrointestinal tract. However, many other suggested biomarkers remain solely correlative, often lacking a causative link to the underlying disease mechanisms possibly explaining their lack in sensitivity and specificity. |
| format | Online |
| id | doab-20.500.12854ir-73785 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-737852024-03-31T13:08:20Z Pathophysiologic Insights from Biomarker Studies in Neurological Disorders Ruck, Tobias Moccia, Marcello Warnecke, Tobias Bittner, Stefan biomarker pathophysiology neuroimmunology neurodegeneration pathomechanism thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKJ Neurology and clinical neurophysiology Neuroimmunological and neurodegenerative disorders are major healthcare issues associated with high individual and socioeconomic burden. For many neurological disorders an early diagnosis is key for efficient management and therapy. However, neural tissues from brain, spinal cord or peripheral nerves are difficult to obtain, and their extraction is often associated with functional deficits. Therefore, in most cases a combination of biomarkers such as radiologic or biochemical findings are used to define a diagnosis in the clinical practice. The development of pathologically-sensitive and easy-to-measure disease biomarkers is a key factor for investigating new medications in phase 2 trials aiming to quickly screen their efficacy, and in phase 3 trials where they are coupled to clinical measures. Moreover, biomarkers are used to predict treatment efficacy and adverse event risk, paving the way for personalized medicine with individual risk assessment and prevention strategies. In the last few decades the enormous technological progress, especially omics technologies, expanded the definition of biomarkers from biochemical and clinical by genetic, proteomic, metabolic or microbial markers. Interestingly, some of the biomarker studies additionally provided important insights into the pathophysiology of neurological disorders. In multiple sclerosis TNF-blocking drugs can promote onset or exacerbation of MS and GWAS (genome-wide association studies) data informed about the underlying mechanisms instructing clinical practice. In Parkinson’s disease (PD), evaluation of Lewy pathology provided new pathophysiological insights attributing PD pathology progression to a prion-like process starting in the gastrointestinal tract. However, many other suggested biomarkers remain solely correlative, often lacking a causative link to the underlying disease mechanisms possibly explaining their lack in sensitivity and specificity. 2021-11-18T16:24:43Z 2021-11-18T16:24:43Z 2020 book ONIX_20211118_9782889636433_917 9782889636433 https://directory.doabooks.org/handle/20.500.12854/73785 eng image/jpeg Attribution 4.0 International https://www.frontiersin.org/research-topics/8041/pathophysiologic-insights-from-biomarker-studies-in-neurological-disorders https://www.frontiersin.org/research-topics/8041/pathophysiologic-insights-from-biomarker-studies-in-neurological-disorders Frontiers Media SA 10.3389/978-2-88963-643-3 10.3389/978-2-88963-643-3 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889636433 340 open access |
| spellingShingle | biomarker pathophysiology neuroimmunology neurodegeneration pathomechanism thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKJ Neurology and clinical neurophysiology Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
| title | Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
| title_full | Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
| title_fullStr | Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
| title_full_unstemmed | Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
| title_short | Pathophysiologic Insights from Biomarker Studies in Neurological Disorders |
| title_sort | pathophysiologic insights from biomarker studies in neurological disorders |
| topic | biomarker pathophysiology neuroimmunology neurodegeneration pathomechanism thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKJ Neurology and clinical neurophysiology |
| topic_facet | biomarker pathophysiology neuroimmunology neurodegeneration pathomechanism thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKJ Neurology and clinical neurophysiology |
| url | ONIX_20211118_9782889636433_917 |